Status:
COMPLETED
Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Aging
Eligibility:
MALE
50-80 years
Phase:
PHASE1
Brief Summary
This study is being done to understand how testosterone, the major male sex hormone, controls the pituitary gland's secretion of growth hormone (GH). GH is an important metabolic hormone, which contro...
Detailed Description
Repletion of testosterone in older men drives pulsatile GH secretion via conjoint facilitation of feedforward by the primary secretagogues GHRH and GHRP and repression of feedback by the dominant inhi...
Eligibility Criteria
Inclusion
- healthy men between the ages of 50 and 80;
- normal weight (within 30% of ideal body weight defined by New York Metropolitan Life tables); and
- normal hematocrit (greater than 38%);
- community dwelling; and
- voluntarily consenting
Exclusion
- recent use of psychotropic or neuroactive drugs (within five biological half-live);
- obesity (outside weight range above);
- anemia (hematocrit \< 38%);
- drug or alcohol abuse, psychosis, depression, mania or severe anxiety;
- acute or chronic organ-system disease;
- endocrinopathy, other than primary thyroidal failure receiving replacement;
- nightshift work or recent transmeridian travel (exceeding 3 time zones within 7 days of admission);
- acute weight change (loss or gain of \> 2 kg in 6 weeks);
- allergy to administered compounds; and
- unwillingness to provide written informed consent.
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00309855
Start Date
December 1 2005
End Date
August 1 2008
Last Update
July 31 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905